Investors

Investors

Company Overview

PharmaKure is a spin out from The University of Manchester. It is a clinical stage biopharmaceutical company dedicated to the treatment of neurodegenerative diseases. The company’s core activities are researching, developing, commercializing & repositioning drugs for the treatment of Alzheimer’s, Parkinson’s & rare prion diseases. An important aspect is the combination of repurposed drugs with proprietary diagnostic ‘biomarkers’ which allows targeted therapy, thereby giving better clinical outcomes

PharmaKure is a clinical stage company, undertaking human trials:

  1. ALZmetrix® is PharmaKure’s unique blood- biomarker assay. A clinical study is underway with Alzheimer’s Disease patients.
  2. A Phase 2a, multiple ascending dose clinical trial of PharmaKure’s lead drug candidate for Alzheimer’s Disease is underway.
  3. PARKmetrix® is PharmaKure’s propriety blood- biomarker assay for diagnosis of Parkinson’s Disease.

If you have any questions, feel free to contact us.

Investor Opportunity

Want to learn more, feel free to contact us.

Contact

Press Releases

Press Releases

View